Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Iterum Therapeutics plc

$0.03

-0.01 (-28.57%)

Last traded Mar 31, 2026. This price is not current.

D 23Pipeline Score Overvalued Pharma · Commercial
Market Cap
3.72 M
EPS
-0.75
P/E Ratio
-
Value Trade
2.64 M
-81.93 %
Week
-87.95 %
1 Month
-89.97 %
3 Month
-95.59 %
6 Month
-99.86 %
5 Year
-99.98 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
65.74 M
52 Week Range
0.03 - 1.42
% held by Insiders
0.79 %
% held by Institutions
3.65 %
Enterprise Value
26.45 M
Total Shares
53.31 M
Short %
18.07 %
Float Shares
51.77 M
Company Description
HQ: 3 DUBLIN LANDINGS, DUBLIN 1, L...
Founded:2015
Employees:9
https://www.iterumtx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2024-10-25
Oral Sulopenem
PDUFA Date
PDUFA
Approved
–
–
–
2024-10-25
Oral Sulopenem
PDUFA Date
PDUFA
Approved
–
–
–
2024-10-25
Oral Sulopenem
PDUFA Date
PDUFA
Approved
–
–
–
Unlock 2 more historical catalysts
Drug Pipeline Intelligence
D23
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 22%
Micro Cap
(rank 729 of 933)
Percentile Rank
Iterum Therapeutics plc faces pipeline headwinds (23/100), with $375M risk-adjusted pipeline value, led by Sulopenem etzadroxil/probenecid in Urinary Tract Infections (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Sulopenem-Etzadroxil/Probenecid
Small molecule		Intra Abdominal InfectionsPhase 3NCT0335857656% $324M COMPLETED 674 - -Oct 2, 2019 -Dec 1, 2020
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
sulopenem
Fast Track
uncomplicated urinary tract infections
Phase 3
2024-01-30

sulopenem success: 61.7%; augmentin success: 55.0%

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority t

Read More
sulopenem
Fast Track
uncomplicated urinary tract infections
Phase 3
2024-01-30

sulopenem success: 61.7%; augmentin success: 55.0%

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority t

Read More
sulopenem
Fast Track
uncomplicated urinary tract infections
Phase 3
2024-01-30

sulopenem success: 61.7%; augmentin success: 55.0%

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Phase 3 REASSURE Trial Met Primary Endpoint of Non-Inferiority t

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ITRM
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ITRM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ITRM ranks across every disease it competes in
Competitive Position is a premium feature
See how ITRM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial